Full Text View
Tabular View
No Study Results Posted
Related Studies
PUVA Versus PUVA + IFN Alpha 2a in Mycosis Fungoides (MF99)
This study has been terminated.
( Insufficient accrual )
Study NCT00630903   Information provided by Madrilenian Group of Cutaneous Lymphomas

First Received on February 28, 2008.   Last Updated on March 6, 2008   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Additional conditions recognized in this trial
Lymphoma
Lymphoma, T-Cell
Lymphoma, T-Cell, Cutaneous
Mycoses
Mycosis Fungoides
More general conditions related to this trial
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoma, Non-Hodgkin
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Interventions listed in this trial
PUVA (8MOP + UVA) + IFN
PUVA (8-MOP + UVA)
Additional drug interventions recognized in this trial
Interferon Alfa-2a
Interferon-alpha
Methoxsalen
More general drug interventions related to this trial
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Anti-Infective Agents
Antineoplastic Agents
Antiviral Agents
Dermatologic Agents
Growth Inhibitors
Growth Substances
Immunologic Factors
Pharmacologic Actions
Photosensitizing Agents
Physiological Effects of Drugs
Radiation-Sensitizing Agents
Therapeutic Uses
Sponsors listed in this trial
Madrilenian Group of Cutaneous Lymphomas


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services